Diversified Trust Co Cuts Stock Position in Omnicell, Inc. $OMCL

Key Points

• Diversified Trust Co dramatically reduced its stake in Omnicell, Inc. by 67.4%, owning only 7,395 shares after selling 15,265 during the second quarter.
• Omnicell reported earnings of $0.45 per share for the quarter, exceeding expectations, and had revenue of $290.56 million, a 5% increase from the previous year.
• Analysts have mixed ratings on Omnicell, with a consensus rating of "Moderate Buy" and a price target average of $46.71.

Diversified Trust Co lessened its stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 67.4% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,395 shares of the company's stock after selling 15,265 shares during the quarter. Diversified Trust Co's holdings in Omnicell were worth $217,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Omnicell by 22.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 119,181 shares of the company's stock worth $5,306,000 after purchasing an additional 21,847 shares in the last quarter. GAMMA Investing LLC increased its stake in Omnicell by 2,892.5% during the 1st quarter. GAMMA Investing LLC now owns 43,211 shares of the company's stock worth $1,511,000 after buying an additional 41,767 shares in the last quarter. Bridge City Capital LLC increased its stake in Omnicell by 1.6% during the 1st quarter. Bridge City Capital LLC now owns 40,136 shares of the company's stock worth $1,403,000 after buying an additional 650 shares in the last quarter. Accurate Wealth Management LLC increased its position in shares of Omnicell by 27.4% during the first quarter. Accurate Wealth Management LLC now owns 36,131 shares of the company's stock worth $1,263,000 after purchasing an additional 7,762 shares in the last quarter. Finally, Illinois Municipal Retirement Fund increased its position in shares of Omnicell by 10.2% during the first quarter. Illinois Municipal Retirement Fund now owns 26,550 shares of the company's stock worth $928,000 after purchasing an additional 2,456 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company's stock.

Omnicell Trading Down 0.4%

Shares of OMCL opened at $30.88 on Thursday. The firm has a 50-day moving average price of $31.17 and a 200 day moving average price of $30.76. Omnicell, Inc. has a 12-month low of $22.66 and a 12-month high of $55.74. The company has a current ratio of 1.42, a quick ratio of 1.24 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $1.42 billion, a P/E ratio of 61.76, a P/E/G ratio of 6.77 and a beta of 0.82.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The business had revenue of $290.56 million during the quarter, compared to analysts' expectations of $275.57 million. During the same quarter in the prior year, the company posted $0.51 EPS. The business's revenue for the quarter was up 5.0% on a year-over-year basis. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. Sell-side analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current year.

Wall Street Analyst Weigh In

OMCL has been the subject of several research reports. Wells Fargo & Company boosted their price target on Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research report on Monday, July 21st. Piper Sandler dropped their target price on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a report on Monday, August 11th. Finally, Wall Street Zen cut shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 9th. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $46.71.

Insider Buying and Selling at Omnicell

In other news, EVP Corey J. Manley sold 3,880 shares of the stock in a transaction on Friday, September 12th. The stock was sold at an average price of $33.25, for a total transaction of $129,010.00. Following the completion of the transaction, the executive vice president directly owned 110,653 shares in the company, valued at approximately $3,679,212.25. This represents a 3.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.52% of the company's stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.